Paper12833461
A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.
Agrawal NR and 5 others. Cancer, 2003. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Papers, record 12833461. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/12833461
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Asparaginase | Major topic |
| Multiple Myeloma | Major topic |
| Polyethylene Glycols | Major topic |
| Adult | |
| Aged | |
| Enzymes, Immobilized | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Treatment Outcome |
Source PubMed
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40905331 | Asparaginase and Autophagy Inhibitors Effectively Remove Senescent Cells by Synergistically Limiting Asparagine Supply. | Aging Cell | 2025 | https://conductscience.org/library/papers/40905331 | PubMed |
| 33763336 | Impact of Lifestyle Behaviors on Cancer Risk and Prevention. | J Lifestyle Med | 2021 | https://conductscience.org/library/papers/33763336 | PubMed |
| 32130706 | The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response. | Adv Exp Med Biol | 2020 | https://conductscience.org/library/papers/32130706 | PubMed |
| 30792264 | Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia. | Mol Cell Proteomics | 2019 | https://conductscience.org/library/papers/30792264 | PubMed |
| 29212306 | Oncogene-Driven Metabolic Alterations in Cancer. | Biomol Ther (Seoul) | 2018 | https://conductscience.org/library/papers/29212306 | PubMed |
| 29101342 | A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro. | Sci Rep | 2017 | https://conductscience.org/library/papers/29101342 | PubMed |
| 27822561 | Oncogene-directed alterations in cancer cell metabolism. | Trends Cancer | 2016 | https://conductscience.org/library/papers/27822561 | PubMed |
| 25664771 | Engineering of Helicobacter pylori L-asparaginase: characterization of two functionally distinct groups of mutants. | PLoS One | 2015 | https://conductscience.org/library/papers/25664771 | PubMed |
| 22645686 | Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications. | J Drug Deliv | 2012 | https://conductscience.org/library/papers/22645686 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/12833461
GET https://conductscience.org/api/papers/v1/12833461/authors